FSSAI opens three cases against Nestlé India over infant nutrition product claims
FSSAI has initiated three adjudication cases involving NAN Excella Pro and Lactogen Pro over alleged non-compliant claims and biotin content. Nestlé India said its products and labels comply with applicable rules and had been cleared by FSSAI’s expert committee.
What happened
FSSAI initiated three cases against Nestle India over alleged non-compliant claims and biotin content in NAN Excella Pro and Lactogen Pro infant nutrition
Key facts
- Three adjudication cases
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
- Section 3 of the Infant Milk Substitutes Act, 1992
- 1.4% share-price decline
- ₹1,353.10
What changed
FSSAI initiated three cases against Nestle India over alleged non-compliant claims and biotin content in NAN Excella Pro and Lactogen Pro infant nutrition products. Nestle says labels and products comply with regulations and were approved by FSSAI’s expert committee.
Why this matters
Three FSSAI adjudication cases raise regulatory and reputational risk for Nestlé India’s infant-nutrition business, though the company’s stated compliance and prior expert-committee clearance may limit near-term downside.
What to watch
- FSSAI adjudication notices, hearing dates, interim orders and final penalty or corrective-action decisions.
- Whether FSSAI orders product recall, sale suspension, relabeling, advertising withdrawal or merely documentation changes.
- Details of the alleged non-compliant claims and biotin-content findings, including whether they concern formulation, label wording or testing methodology.
- Nestlé India's disclosure of provisions, inventory write-downs, supply disruption or sales impact in quarterly results.
- Any expansion from NAN Excella Pro and Lactogen Pro to additional Nestlé products or a broader sector-wide FSSAI enforcement action.
Also reported by
- Mint · Companies — Same time